ACAD Q4 2018 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+36.7% YoY

Gross Profit

$55M92.6% margin

Operating Income

-$67M-112.9% margin

Net Income

-$65M-109.9% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$40M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$540M

Total Liabilities

$61M

Stockholders' Equity

$479M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$44M	+36.7%
Gross Profit	$55M	$40M	+38.4%
Operating Income	-$67M	-$70M	+3.9%
Net Income	-$65M	-$69M	+4.9%